Human genetic evidence is one of the most powerful tools available to de-risk drug targets, yet its potential remains largely untapped in early-stage R&D. Unlike animal models or observational data, human genetics delivers causal evidence directly from human biology, at the stage where it changes decisions. For the first time, the data and tools now exist to leverage human genetics rigorously and at scale across therapeutic areas.
of Phase II failures are driven by insufficient evidence that the target causally drives disease in humans.
human genetic datasets on clinical outcomes across therapeutic areas and molecular traits available for causal analyses
from target and indication to a decision-ready evidence report
Through our MendelyticsTM platform, our team delivers deep genetic intelligence in weeks, without compromising the analytical rigor your decisions depend on. We maintain scientific integrity and transparency. Every output comes with full methodological transparency, so you understand not just what we found, but why you can trust it.
Whether you’re a biotech building a programme, a pharma team assessing an asset, an investor deciding whether to back a programme, or a CRO strengthening the evidence behind your client work, AquilaGen delivers the evidence layer specific to your question.
Add genetics-driven target validation to your preclinical and clinical workflows, strengthening the scientific case you deliver to pharma clients.
Independent causal analysis for hypothesis testing, methodological support for grant applications and postgraduate research, and training courses in causal inference methods.
AquilaGen is your dedicated genetics team. We embed analytical rigour, clinical expertise and commercial fluency into your programme, translating genetic findings into the decisions that matter most: which target to progress, which indication to prioritize, and where the human evidence is strong enough to act on. Our cross-disciplinary team brings together statistical genetics, clinical medicine, and drug development expertise to systematically integrate causal human evidence across the life sciences ecosystem.
